The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Wu, T., Rayner, C. K., & Horowitz, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0164 · Cited by 23
Jeha, G. S., & Heptulla, R. A. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00159.x · Cited by 22
Gastric Inhibitory Polypeptide Analogues
Holst, J. J. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00002 · Cited by 22
Self-citationTseng, C., & Zhang, X. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00061-6 · Cited by 22
Exenatide: A Novel Approach for Treatment of Type 2 Diabetes
Mikhail, N. E. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000240730.86237.b6 · Cited by 21
HOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17549.x · Cited by 21
Self-citationGLP-1-mediated gene therapy approaches for diabetes treatment
Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 22
Targeting skeletal muscle mitochondrial health in obesity
Pileggi, C. A., Hooks, B. G., McPherson, R., Dent, R. R. M., & Harper, M.-E. (2022) · Clinical Science · doi:10.1042/cs20210506 · Cited by 21
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
Goodarzi, M. O., & Petrov, M. S. (2023) · Drugs · doi:10.1007/s40265-023-01913-5 · Cited by 24
DeFronzo, R. A., Triplitt, & Cersosimo (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4852 · Cited by 23
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 21
Davidson, J. A., Parente, E. B., & Gross, J. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600016 · Cited by 21
Hedetoft, C., Sheikh, S. P., Larsen, S. U., & Holst, J. J. (2000) · Pancreas · doi:10.1097/00006676-200001000-00004 · Cited by 21
Self-citationWhat mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Ahr�n, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1706-6 · Cited by 21
Hui, H., Yu, R., Bousquet, C., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2001-210979 · Cited by 21
Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.027 · Cited by 20
Nauck, M. A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154031 · Cited by 21
Self-citationGlucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Self-citationLengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Trials · doi:10.1186/s13063-023-07164-9 · Cited by 20
Ohara‐Imaizumi, M., Aoyagi, K., Akimoto, Y., Nakamichi, Y., Nishiwaki, C., Kawakami, H., & Nagamatsu, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.043 · Cited by 20
Zhang, S., Wang, S., Puhl, M. D., Jiang, X., Hyrc, K. L., Laciny, E., Wallendorf, M., Pappan, K. L., Coyle, J. T., & Wice, B. M. (2014) · Diabetes · doi:10.2337/db14-1188 · Cited by 21
de Toro‐Martín, J., Fernández‐Millán, E., Lizárraga-Mollinedo, E., López‐Oliva, M. E., Serradas, P., Escrivá, F., & Álvarez, C. (2014) · Endocrinology · doi:10.1210/en.2013-2043 · Cited by 20
Wu, T., Zhang, X., Trahair, L. G., Bound, M. J., Little, T. J., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2813 · Cited by 20
Tura, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., Vilsbøll, T., & Mari, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.006 · Cited by 20
Self-citationHasib, A., Ng, M. T., Tanday, N., Craig, S. L., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3106 · Cited by 20
Heruc, G. A., Horowitz, M., Deacon, C. F., Feinle‐Bisset, C., Rayner, C. K., Luscombe‐Marsh, N. D., & Little, T. J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2014 · Cited by 19
Physiological endocrine control of energy homeostasis and postprandial blood glucose levels.
Gagliardino, J. J. (2005) · PubMed · Cited by 21
Hou, J., Yan, R., Yang, L., Wu, Z., Cuiyan, W. A. N. G., Ding, D., Li, N., Ma, C., & Li, M. (2007) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.60694 · Cited by 20
The GLP‐1 system as a therapeutic target
Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 21
Interorgan crosstalk in pancreatic islet function and pathology
Evans, R. M., & Wei, Z. (2022) · FEBS Letters · doi:10.1002/1873-3468.14282 · Cited by 19
Fernández‐Millán, E., & Guillén, C. (2022) · Biomolecules · doi:10.3390/biom12010104 · Cited by 21
Lodefalk, M., Carlsson‐Skwirut, C., Holst, J. J., Åman, J., & Bang, P. (2010) · Hormone Research in Paediatrics · doi:10.1159/000308168 · Cited by 19
Self-citationCassidy, R. S., Irwin, N., & Flatt, P. R. (2007) · Biological Chemistry · doi:10.1515/bc.2008.019 · Cited by 19
Las hormonas gastrointestinales en el control de la ingesta de alimentos
Álvarez-Crespo, M., González-Matías, L. C., Gil‐Lozano, M., Paz, S. F., Romaní‐Pérez, M., Gago, E. M., & Ferrer, F. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71946-1 · Cited by 22
Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Vallois, D., Niederhäuser, G., Ibberson, M. R., Nagaray, V., Marselli, L., Marchetti, P., Chatton, J., & Thorens, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103277 · Cited by 17
Field, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 19
Fujigaki, Y. (2014) · Medical Science Monitor · doi:10.12659/msm.889872 · Cited by 19
Yu, Y.-W., Hsueh, S., Lai, J.-H., Chen, Y., Kang, S.-J., Chen, K., Hsieh, T.-H., Hoffer, B. J., Li, Y., Greig, N. H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041153 · Cited by 19
Pavlišová, J., Horakova, O., Kalendová, V., Buresova, J., Bardová, K., Holendová, B., Plecitá‐Hlavatá, L., Vacková, Š., Windrichová, J., Topolčan, O., et al. (2020) · Food & Function · doi:10.1039/d0fo01942a · Cited by 20
Ruze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 19
Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 20
Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients
Škrha, J., Hilgertová, J., Jarolimkova, M., Kunešová, M., & Hill, M. (2010) · Physiological Research · doi:10.33549/physiolres.931893 · Cited by 21
Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes
Honka, H., Koffert, J., Kauhanen, S. P., Teuho, J., Hurme, S. A. M., Mari, A., Lindqvist, A., Wierup, N., Groop, L., & Nuutila, P. (2017) · Diabetes · doi:10.2337/db16-0762 · Cited by 19
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 21
Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats
Aulinger, B. A., Perabò, M., Seeley, R. J., Parhofer, K. G., & D’Alessio, D. A. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00298.2019 · Cited by 20
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00297-5 · Cited by 19
Self-citation[Ser2]- and [Ser(P)2]Incretin Analogs
Hinke, S. A., Manhart, S., Kühn‐Wache, K., Nian, C., Demuth, H., Pederson, R. A., & McIntosh, C. H. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311304200 · Cited by 19
GIP: An Inconsequential Incretin or Not?
Pratley, R. E. (2010) · Diabetes Care · doi:10.2337/dc10-0704 · Cited by 19
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 20
Aloke, C., Adelusi, O. A., Onisuru, O. O., Iwuchukwu, E. A., & Achilonu, I. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70277 · Cited by 21
Winzeler, B. F., da Conceição, I., Refardt, J. C., Sailer, C. O., Dutilh, G., & Christ‐Crain, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01420 · Cited by 18
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
Albrechtsen, N. J. W., Møller, A., Martinussen, C., Gluud, L. L., Rashu, E. B., Richter, M. M., Plomgaard, P., Goetze, J. P., Kjeldsen, S. A. S., Hansen, L. H., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14789 · Cited by 18
Self-citationJalleh, R. J., Wu, T., Jones, K. L., Rayner, C. K., Horowitz, M., & Marathe, C. S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac330 · Cited by 18
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 21
Brandsma, M. E., Wang, X., Diao, H., Kohalmi, S. E., Jevnikar, A. M., & Ma, S. (2009) · The Open Biotechnology Journal · doi:10.2174/1874070700903010057 · Cited by 18
Understanding GLP-1 Analogs and Enhancing Patient Success
Kruger, D. F., Bode, B. W., & Spollett, G. R. (2010) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721710374370 · Cited by 18
Effect of alterations in blood volume with bed rest on glucose tolerance
Dandanell, S., Oberholzer, L., Keiser, S., Andersen, A. B., Haider, T., Hilty, M. P., Meinild‐Lundby, A., & Lundby, C. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00624.2016 · Cited by 18
Dudkowski, C., Tsai, M. C., Liu, J., Zhao, Z., Schmidt, E., & Xie, J. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2175-1 · Cited by 18
Craig, S. L., Perry, R. A., Vyavahare, S. S., Ng, M., Gault, V. A., Flatt, P. R., & Irwin, N. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113723 · Cited by 18
Kindmark, H., Pigon, J., & Efendić, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7502 · Cited by 18
Coffee consumption and type 2 diabetes — An extensive review
Bidel, S., Hu, G., & Tuomilehto, J. O. (2007) · Open Medicine · doi:10.2478/s11536-007-0059-6 · Cited by 18
Johnson, K., Edgerton, D. S., Rodewald, T., Scott, M. F., Farmer, B., Neal, D. W., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00642.2007 · Cited by 19
Snook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Lymperopoulos, A., Altsman, V. L., & Stoicovy, R. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157239 · Cited by 24
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 19
Self-citationFluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
de Bray, A., Roberts, A. G., Armour, S. L., Tong, J., Huhn, C., Gatin‐Fraudet, B., Roßmann, K., Shilleh, A. H., Jiang, W., Burgos, N. S. F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01342-6 · Cited by 20
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 19
Mucosal and hormonal adaptations after Roux-en-Y gastric bypass
Feris, F., MCRAE, A. N., Kellogg, T. A., McKenzie, T. J., Ghanem, O. M., & Acosta, A. J. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.020 · Cited by 18
Watkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 20
Self-citationKurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 20
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 19
Assessment of re‐aggregated human pancreatic islets for secondary drug screening
Ramachandran, K., Peng, X., Bokvist, K. B., & Stehno‐Bittel, L. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12622 · Cited by 17
Tudurí, E., Beiroa, D., Porteiro, B., López, M., Diéguez, C., & Nogueiras, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12488 · Cited by 17
Pathak, V., Vasu, S., Flatt, P. R., & Irwin, N. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12227 · Cited by 18
de Luis, D., Domingo, M., Romero, A., Sagrado, M. G., Pacheco, D., Primo, D., & Conde, R. (2012) · American Journal of Surgery · doi:10.1016/j.amjsurg.2011.07.020 · Cited by 18
GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells
Ogata, M., Iwasaki, N., Ide, R., Takizawa, M., & Uchigata, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.143 · Cited by 17
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 18
Zhang, L., Song, X., Zhou, L., Liang, G., Xu, H., Wang, F., Huang, F., & Jiang, G. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0194-9 · Cited by 17
Ruetten, H., Gebauer, M., Raymond, R. H., Calle, R. A., Cobelli, C., Ghosh, A., Robertson, R. P., Shankar, S. S., Staten, M. A., Stefanovski, D., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0022 · Cited by 17
Xie, C., Wang, X., Jones, K. L., Horowitz, M., Sun, Z., Little, T. J., Rayner, C. K., & Wu, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13906 · Cited by 17
Fushimi, Y., Obata, A., Sanada, J., Nogami, Y., Ikeda, T., Yamasaki, Y., Obata, Y., Shimoda, M., Nakanishi, S., Mune, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94896-w · Cited by 17
Down-regulation of pancreatic transcription factors and incretin receptors in type 2 diabetes
Kaneto, H. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.263 · Cited by 18
Palha, A. M., Pereira, S. S., Costa, M. M., Morais, T., Maia, A. F., Guimarães, M., Nora, M. C., & Monteiro, M. P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27062 · Cited by 19
Human Physiology of Genetic Defects Causing Beta-cell Dysfunction
Kettunen, J. L. T., & Tuomilehto, J. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.038 · Cited by 18
Role and development of GLP-1 receptor agonists in the management of diabetes
Egan, J. M., & Chia, C. W. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s4283 · Cited by 19
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Kubota, M., Yamamoto, K., & Yoshiyama, S. (2023) · Cureus · doi:10.7759/cureus.46490 · Cited by 16
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 18
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 19
Kim, T. I., Lee, M., & Kim, S. W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.072 · Cited by 16
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 21
NK cells vs. obesity: A tale of dysfunction & redemption
Barra, C. D., O'Shea, D. B., & Hogan, A. E. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109744 · Cited by 17
Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Self-citationLee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“The promise of GLP1 as a therapeutic target in T2DM was appreciated when it was demonstrated that it contributes up to 70% of insulin production in response to nutrition intake [38].”
BackgroundDhesi, B., Chauhan, H., & Basu, A. (2013) · Practical Diabetes · doi:10.1002/pdi.1767 · Cited by 4
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
